lilly glp-1 drugs orforglipron oral phase 3 weight loss trial Lilly is now pharma's top

Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease

Although the muscle loss observed after GLP-1 treatments seem to be in line with the levels of expected weight loss, maintaining or increasing muscle mass can also prevent or retard weight regain in all individuals using these medications

Circu ML, Stringer S, Rhoads CA, Moyer MP, Aw TY

Sagging Skin Sagging skin, or skin laxity, can also happen

Semaglutide and Cardiovascular Outcomes [PMID: 38381684] Laboratory literature summary: Semaglutide and Cardiovascular Outcomes

Another benefit was that 20 percent of patients with type 2 diabetes who took liraglutide were able to reduce or discontinue their treatment with insulin (Holst 2024)